Vimarsana
Biggest News Aggregation in the World

Page 2 - Gavin Macbeath News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gavin Macbeath. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gavin Macbeath Today - Breaking & Trending Today

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years - Vimarsana News

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

WALTHAM, Mass., Nov. 30, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment...

TScan Therapeutics Up 5% On FDA Clearance For TSC-203-A0201 - Vimarsana News

TScan Therapeutics Up 5% On FDA Clearance For TSC-203-A0201

Shares of TScan Therapeutics, Inc. (TCRX) are up 5% on Tuesday after the company announced that it received FDA clearance for its IND application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME).

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME - Vimarsana News

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapyWALTHAM, Mass., Aug. 29, 2023 -- TScan...

TScan Therapeutics : Management Change - Form 8-K - Vimarsana News

TScan Therapeutics : Management Change - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | June 16, 2023

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors - Vimarsana News

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on... | June 6, 2023